JNJ-6640 is an inhibitor targeting Mycobacterium PurF, the first enzyme in the de novo purine biosynthesis pathway, with potent antitubercular activity. It exhibits bactericidal properties against Mycobacterium tuberculosis in vitro, with a MIC90 of 8.6 nM. By disrupting de novo purine biosynthesis, JNJ-6640 inhibits Mycobacterium tuberculosis DNA replication in vivo. Demonstrating antitubercular efficacy in acutely infected mice, JNJ-6640 is applicable for tuberculosis research.
Target:
Antibacterial
* VAT and and shipping costs not included. Errors and price changes excepted
